SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Biotechnology

Healthcare
$17.95 +4.02%

+$0.31 today

Market cap
$3.66B
Beta
2.53
P/E (TTM)
-47.3
EPS (TTM)
-$0.17
52W Low $1.39High $9.51

Volume 35.53M

Average 7.79M

SLS Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

SELLAS Life Sciences Group, Inc.NASDAQ: SLS

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Sep 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 202.44M shares rose 86.8% year over year, behind the +94.5% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 7.0% from the prior quarter. Over 3 fiscal years it compounded at +77.8% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +86.8% toward the trailing-twelve-month pace of +94.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
202.44M+7.0% QoQ
Last fiscal yearDec 2025
109.05M+78.2% YoY
LTMSep 2026
179.3M+94.5% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.8%——
1 year+78.2%——
3-year CAGR+77.8%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
109.05M USD
Year-over-year change
+78.2%
4-year CAGR
+62.9%

Weighted Avg Shares (Diluted) vs competitors

How SLS compares with its peers on the latest reported figures

  • SLS's LTM Sep 2026 weighted avg shares (diluted) of 179.3M shares is the 2nd highest of the 11 companies compared; the peer median is 88.95M shares.
  • Its year-over-year change of +94.5% is the highest of 11, against a peer median of +11.2%.
  • Over three fiscal years its annual growth of +77.8% compares with a peer median of +18.4%.
SLS Competitors Peer median
Weighted Avg Shares (Diluted) for SLS and competitors
Company Period LTM YoY 3-year CAGR
INCYIncyte CorporationLTM Jun 2026205.31M +3.9%-3.6%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +94.5%+77.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026108.1M +31.0%+21.3%
IMNMImmunome, Inc.LTM Sep 2026106.83M +34.8%+93.1%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
AAPGAscentage Pharma Group InternationalFY202589.03M +17.9%+75.5%
IDYAIDEAYA Biosciences, Inc.LTM Mar 202688.86M +4.6%+28.8%
PRLDPrelude Therapeutics IncorporatedLTM Mar 202674.4M -1.9%+17.6%
MGNXMacroGenics, Inc.LTM Mar 202663.26M +0.8%+0.9%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 202640.11M +19.2%+4.7%
CBIOCrescent Biopharma, Inc.LTM Mar 202617.74M -57.8%-41.7%
Peer median (excluding SLS) 88.95M+11.2%+18.4%

Competitors are the stored peer set for SLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue7.6M1M000
Cost of Revenue200K100K000
Gross Profit7.4M900K000
Gross Margin97.4%90.0%———
Research & Development21.37M30.27M24.01M19.1M16.02M
Selling, General & Admin11.32M12.58M13.86M12.42M12.25M
Operating Expenses32.69M42.85M37.87M31.51M28.27M
Depreciation & Amortization1.27M457K37.87M31.51M0
EBITDA(18.32M)(31.49M)529K632K(26.86M)
EBITDA Margin-241.1%-3149.3%———
Operating Income(25.29M)(41.95M)(37.87M)(31.51M)(28.27M)
Operating Margin-332.8%-4195.0%———
Interest Income6K317K525K632K1.41M
Interest Expense00000
Other Income / Expenses4.36M649K529K632K1.41M
Income Before Tax(20.94M)(41.3M)(37.34M)(30.88M)(26.86M)
Pre-Tax Margin-275.5%-4130.1%———
Income Tax Expense(237K)0000
Net Income(20.7M)(41.3M)(37.34M)(30.88M)(26.86M)
Net Margin-272.4%-4130.1%———
EPS (Basic)(1.34)(2.13)(1.34)(0.50)(0.25)
EPS (Diluted)(1.34)(2.13)(1.34)(0.50)(0.25)
Weighted Avg Shares15.48M19.4M27.78M61.2M109.05M
Weighted Avg Shares (Diluted)15.48M19.4M27.78M61.2M109.05M

SELLAS Life Sciences Group, Inc.

NASDAQ:SLS

Intrinsic Alpha fair value

Locked

Current Price

$17.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.